AstraZeneca Pharma India Ltd Q3 Results
- BSE: 506820
- NSE: ASTRAZEN
- ISIN: INE203A01020
- Sector: Biotechnology & Drugs
BSE
8,550.00
-73.00 (-0.85%)
-73.00 (-0.85%)Volume207.00
Updated: Fri 6 Feb, 2026 | 15:29:02
NSE
8,557.50-64.00 (-0.74%)
-64.00 (-0.74%)Volume4.57 K
Updated: Fri 6 Feb, 2026 | 15:29:33
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 24
Note: Comparison is on QoQ basis
Quarterly - AstraZeneca Pharma India Ltd Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 24 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 405.92 | 364.80 | 11.27% | 294.44 | 37.86% |
| Depreciation/ Amortization | 9.07 | 9.32 | -2.68% | 3.70 | 144.83% |
| Operating Income | 34.37 | 43.20 | -20.44% | 11.35 | 202.76% |
| Net Income | 30.85 | 38.43 | -19.72% | 15.80 | 95.24% |
| Other Operating Expenses Total | 31.33 | 36.98 | -15.28% | 50.89 | -38.43% |
| Net Income Before Taxes | 42.02 | 51.03 | -17.66% | 20.40 | 105.99% |
| Total Revenue | 440.29 | 408.00 | 7.91% | 305.79 | 43.98% |
| Selling/ General/ Admin Expenses Total | 84.94 | 92.57 | -8.24% | 91.56 | -7.23% |
| Diluted Normalized EPS | 22.19 | 15.37 | 44.39% | 6.32 | 251.15% |